콘텐츠로 이동

국소 진행성 또는 전이성 고형암 환자를 대상으로 하는 AVA6103 임상 1상 시험

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

안내

이 페이지는 자동 수집·AI 요약된 정보입니다. 의료 조언이 아니며, 치료 결정은 반드시 담당 의료진과 상의하세요. 응급 상황은 응급 가이드 또는 119.

항목 내용
등록번호 NCT07454642
상태 모집 중
단계 1상
시험 약물/중재 AVA6103
대상 질환 Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
스폰서 Avacta Life Sciences Ltd
연령·성별 18 Years ~ 제한 없음 · ALL
목표 인원 174
시작 / 1차 완료 예정 2026-03-31 / 2029-01
국내 실시기관 없음
실시 국가 1개국, 기관 7곳 (United States)
결과 게시 아니오
최근 갱신 2026-10-05

문의처 (등록된 중앙 연락처)

  • Avacta Clinical Team +44 (0)20 3911 0353 clinicaltrials@avacta.com

국내 기관 참여 문의는 해당 병원 임상시험센터 또는 담당 주치의를 통해 하세요. 참여 방법 안내

시험 개요

이 연구는 국소 진행성 또는 전이성 고형암(췌장암 포함) 환자를 대상으로 신약 AVA6103 단독요법을 평가하는 최초 인간 대상(first-in-human) 공개, 다기관 임상 1상 시험입니다. 연구는 안전성, 내반성, 최대내생용량(MTD) 및 권장 2상 용량(RP2D)을 평가하는 용량 증량(Phase 1a)과 이후 진행되는 용량 확장(Phase 1b) 단계로 구성됩니다. 총 174명의 환자를 목표로 진행하며, 한국 내 임상 기관은 없습니다.

  • 임상 1상 시험으로 국소 진행성 또는 전이성 고형암 환자 174명을 대상으로 합니다.
  • 중재 치료는 AVA6103 단독요법을 정맥 투여합니다.
  • 용량 증량 단계(Phase 1a)와 용량 확장 단계(Phase 1b)로 나누어 진행됩니다.

참여 조건 (AI 정리, 원문 확인 필요)

선정 기준: 1. 연구에 대해 충분히 안내받고 동의서에 서명한 자. 2. 18세 이상의 남성 또는 여성. 3. 췌장관암종(PDAC) 등 FAP 양성 종양으로 확인되며 표준 치료를 받았거나 부적합한 자. 4. 예상 여명이 3개월 이상인 자. 5. ECOG 수행 능력 상태가 0 또는 1인 자. 6. 이전 치료의 급성 독성에서 회복된 자. 7. 적절한 조혈 기능(절대중성구수 1.5 x 10^9 cells/L 이상, 혈색소 9.0 g/dL 이상, 혈소판 100,000/uL 이상 등)을 갖춘 자. 8. 적절한 간 기능(총 빌리루빈, AST, ALT 기준 충족)을 갖춘 자. 9. 크레아티닌 청소율이 60 mL/min 이상인 신장 기능을 갖춘 자. 10. 가임기 여성의 임신 테스트 음성. 11. 피임 요건을 준수하는 자. 12. 프로토콜 및 생검 요구사항을 준수할 의향이 있는 자. 제외 기준: 1. 활성 또는 의심되는 중추신경계(CNS) 전이가 있는 자. 2. 2년 이내에 다른 악성 종양 병력이 있는 자. 3. 프로토콜 준수에 영향을 미칠 수 있는 조절되지 않는 동반 질환이 있는 자. 4. 연구 참여에 위험이 되는 임상적으로 불안정한 질환이 있는 자. 5. HIV, 활동성 B형 또는 C형 간염 등 알려진 감염 병력이 있는 자. 6. 최근 심각한 감염 이력이 있는 자.

선정/제외 기준 원문 (영어)

Inclusion Criteria:

  1. The subject is fully informed about the study and is willing and able to sign the informed consent form (ICF).
  2. Male or female subjects, ≥18 years of age.

  3. Subjects with the following tumors reported to be FAP positive, with histological or cytological confirmation of a locally advanced (unresectable) and/or metastatic progressing disease that have received all standard-of-care or Food and Drug Administration (FDA) approved treatments, or are ineligible for those treatments, or decline those treatments

  4. Cervical/vulvar cancer

  5. SCLC
  6. Gastric/GEJ cancer
  7. PDAC
  8. CRC
  9. HR+ breast cancer
  10. Has a life expectancy of ≥3 months, in the opinion of the investigator.
  11. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  12. Has recovered from all acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure (must have resolved to CTCAE Grade ≤1 or returned to baseline, whichever is greater. Exceptions include alopecia and peripheral neuropathy, which can be up to CTCAE Grade 2).

  13. Has adequate hematological function (applies only to subjects not receiving therapeutic anticoagulation; subjects receiving therapeutic anticoagulation should be on a stable dose):

  14. Absolute neutrophil count of ≥1.5 × 109 cells/L. Subjects with documented benign ethnic neutropenia may be enrolled with an absolute neutrophil count of ≥1.0 × 109 cells/L

  15. Hemoglobin ≥9.0 g/dL.
  16. Platelet count of ≥100,000/µL.
  17. International normalized ratio and activated partial thromboplastin time ≤1.5 times the ULN, except for subjects on direct acting anticoagulation.

  18. Has adequate liver function:

  19. Total bilirubin 1.5 × ULN (except for subjects with documented Gilbert's Syndrome or liver metastases who must have a total bilirubin \<3 × ULN).

  20. AST and ALT ≤2.5 × ULN (in subjects with liver metastases, \<5 × ULN is allowed).
  21. Has adequate renal function as defined by creatinine clearance ≥ 60 mL/min by the Cockcroft-Gault equation.
  22. Women of childbearing potential and women who have ≤2 years amenorrhea after start of menopause, must have a negative serum or urine pregnancy test within 7 days prior to Cycle 1 Day 1.

  23. Contraception requirements:

    1. Female subjects of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method (Pearl Index failure rate \< 1% per year) during the treatment period and for at least 6 months after the last dose of study drug.
    2. Male subjects with female partners of childbearing potential must agree to using 2 acceptable methods of contraception (Pearl Index failure rate \<1% per year), including a barrier method (with or without spermicide) during the treatment period and for at least 6 months after the last dose of study drug.
    3. Male subjects must agree to refrain from sperm donation during the treatment period and for at least 6 months after the last dose of study drug.

  24. The subject is willing and able to comply with the protocol, including any PK blood sampling and tumor biopsy requirements and agrees to return to clinic for follow-up visits and examinations.

    1. For subjects in Phase 1a or 1b, on treatment tumor biopsy is optional, except for patients assigned to backfill slots, where biopsies are mandatory.

    -

Exclusion Criteria:

  1. Has active or suspected central nervous system (CNS) metastases as determined by the Investigator. Subjects may still be eligible if CNS metastases are definitively treated with radiotherapy, the subject is asymptomatic, not requiring corticosteroids (prednisone or equivalent must be 10 mg/day or less), and have had repeat imaging no less than 4 weeks after completing radiotherapy to document stability.
  2. Subjects who have any history of an active (requiring treatment) other malignancy (except any in-situ carcinoma, non-melanoma skin carcinoma and early prostate cancer with a normal prostate-specific antigen) within 2 years of study entry.
  3. Has a significant, uncontrolled, concomitant disease that could affect compliance with the protocol.
  4. History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease (including, but not limited to, cardiopulmonary, renal, metabolic, hematologic or psychiatric) other than their primary malignancy, that in the opinion of the Investigator would pose a risk to subject safety or interfere with study evaluations, procedures, or completion.

  5. History of known infection is defined as:

  6. HIV infection defined as: An AIDS-defining infection within 12 months of planned study Day 1. Subjects on anti-retroviral treatment who are not established on anti-retroviral treatment for ≥4 weeks and who have a viral load >400 copies/mL prior to study Day 1.

  7. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection defined as: a positive hepatitis B surface antigen (HBsAG) test at screening. Subjects with a past or resolved HBV infection (defined as having a negative HBsAG test and a positive antibody to hepatitis B core antigen antibody test) are eligible. Subjects positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  8. Chronic HBV (HBsAg positive, undetectable or low HBV DNA and normal ALT).
  9. Subjects with active disease who are not on/have not initiated anti-retroviral treatment prior to study Day 1.
  10. Subjects with untreated HCV infection or have not completed treatment for HCV infection.
  11. Subjects with treated HCV infection but with an HCV viral load above the level of quantification.
  12. Has a severe infection (requiring IV antibiotic treatment) within 21 days prior to Cycle 1, Day 1 including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
  13. Has any other clinically significant active disease, metabolic dysfunction, physical examination finding, altered mental status, clinical laboratory finding, or reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug in the opinion of the investigator.
  14. Has had major surgery within 21 days prior to Cycle 1, Day 1 (excluding biopsies) or anticipates the need for major surgery during study treatment.
  15. Is a pregnant or breastfeeding woman.
  16. Has a known hypersensitivity to any of the components of AVA6103 or any excipient of the product or to other topoisomerase 1 (TOP1) inhibitors.
  17. Has received prior investigational therapy (defined as a treatment for which there is no Regulatory Authority-approved indication) within 5 half-lives or 28 days (whichever is shorter) of Cycle 1 Day 1.

  18. Has received any approved anticancer therapy, including chemotherapy or hormonal therapy, within 14 days (or 5 half-lives, whichever is shorter) prior to Cycle 1 Day 1, with the following exception:

    1. Is planned for on-study treatment or has received within 14 days (or 5 half-lives, whichever is shorter) prior to Cycle 1 Day 1.
    2. Subjects who have received a monoclonal antibody.

  19. Is currently taking St John's Wort, any drugs that are a strong inhibitor or inducer of cytochrome P450 (CYP)3A4, CYP1A2, CYP2D6, or P-glycoprotein (P-gp) such as ketoconazole, Nifedipine, erythromycin and fentanyl.

  20. Drugs which are strong inhibitors of multidrug resistance protein (MRP)2, MRP3 or MRP4.
  21. Is planned for on study treatment with any drugs that are sensitive CYP3A4 or organic anion transporting polypeptide (OATP)1B3 substrates, and/or where these drugs will be in the systemic circulation at the start of Cycle 1, Day 1. For this protocol, it means that the drug must not be used within 5 half-lives (or 5 days, whichever is longer) prior to AVA6103 Cycle 1 Day 1 and during study treatment.
  22. Has received granulocyte-colony stimulating factor (G-CSF), or red blood cell or platelet transfusion within 14 days prior to Cycle 1 Day 1.
  23. Has received radiotherapy within 28 days prior to Cycle 1 Day 1, except for limited field palliative radiotherapy, which requires at least a 7-day washout period.
  24. Has received live attenuated vaccine within 30 days prior to Cycle 1 Day 1. Note: If a COVID-19 vaccine is administered it should be done >96 hours prior to AVA6103 administration. For the dose escalation phase, it should be administered after completion of the DLT period.
  25. QT interval corrected through use of Fridericia's formula (QTcF) > 470 ms demonstrated by at least two single ECGs ≥ 30 minutes apart.

출처: ClinicalTrials.gov · 수집 2026-10-06 · 갱신 2026-10-06

댓글 기능은 아직 설정 전입니다 (관리자: docs/SETUP.md의 giscus 항목 참고). 의견은 GitHub Discussions에 남겨 주세요.